Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β because we believe great analysis should be held accountable.
The Asymmetric Trap Hidden in Mirum Pharmaceuticals (MIRM)
Mirum Pharma (MIRM) shows explosive revenue growth and strong cash, yet has 20% short interest. Major funds are accumulating while retail bets on puts, creating a high-tension setup ahead of key positive trial data.
The Anatomy of a Collapse: Decoding POET's 47% Plunge
POET stock plunged 47% after Marvell canceled orders due to POET's confidentiality breach. Options and dark pool data showed institutional investors likely had advance knowledge and were shorting before the public announcement.
The AI Mirage: Why AXTI's 400% Melt-Up is a Ticking Time Bomb
AXTI's 400% AI-driven surge masks unprofitability. Insiders dumped millions in shares as retail bought the narrative, signaling a dangerous disconnect from fundamentals.
The Shadow Accumulation of Prelude Therapeutics: Why The Obvious Dilution is a Trap
Institutional investors, not retail, drove Prelude's recent stock offering. Major funds like OrbiMed increased their stakes, signaling strong confidence in upcoming clinical catalysts despite the apparent dilution.
The Anatomy of a Stealth Squeeze: Why Acrivon Therapeutics is Smart Money's Best Kept Secret
Acrivon Therapeutics is a biotech stock showing signs of a major institutional accumulation phase, with management's strategic moves and hidden market data pointing to an imminent, powerful price surge.
The Biotech Anomaly: Why the Street is Dead Wrong on ACADIA Pharmaceuticals
ACADIA's stock fell despite strong 2025 earnings, $391M net income, and a $1.28B 2026 outlook. Major funds are accumulating shares, and recent trading data signals a powerful reversal is underway.
The Anatomy of a Biotech Shakeout: Why CytomXβs Post-Offering Bleed is a Dark Pool Mirage
CytomX's post-offering stock drop hides major institutional buying in dark pools, signaling a bullish accumulation phase, not a sell-off.
The Invisible Hand Strangling ZYME's Shorts: A Deep Dive into Biotech's Quietest Squeeze
ZYME's stock surge is driven by a hidden institutional squeeze, not just positive news. Data shows massive off-exchange buying overpowering short sellers, forcing a capitulation.
The Anatomy of a Stealth Squeeze: What the Dark Pools Are Screaming About ARTV
Dark pool data suggests ARTV's surge is a smart money-driven repricing, not irrational. Insiders swapped options for stock before a pivotal autoimmune therapy pivot, signaling major upside.
The Darovasertib Mirage: Decoding the Hidden Institutional Exit in IDYA
Institutional investors heavily sold IDYA stock off-exchange after positive trial data, revealing a hidden distribution event despite the public rally.
The $2.25 Billion "Sell The News" Illusion: What Dark Pools Are Hiding in Arbutus Biopharma
Despite a post-settlement price drop, dark pool data reveals aggressive institutional accumulation in Arbutus Biopharma, not selling.
Rocket Lab (RKLB): The Stealth Re-Accumulation Following the Great Distribution
Rocket Lab's stock fell 30% after a planned insider sell-off. The distribution phase is now over, signaling a potential stealth re-accumulation by smart money.
The Matrix-M Mirage: Why the Market is Mispricing Novavax's Sum-of-the-Parts
Novavax is undervalued. It holds $751M cash, has profitable licensing deals for its Matrix-M tech, and faces activist pressure to unlock shareholder value. The market ignores this shift.
The Anatomy of a Manufactured Markdown: Uncovering the Deep-Value Disconnect in CAI
CAI stock is down 50% despite 97% revenue growth. The plunge is a market illusion, with dark pool data showing heavy institutional accumulation, not a fundamental failure.
The Negative Enterprise Value Anomaly: Decoding the $150M Hidden Reboot of OKUR
OKUR's stock trades at a negative enterprise value after a $150M private placement. Investors buy the company's IP and cash for less than the cash itself, a deep-value anomaly.
The Anatomy of a Washout: Why Zai Lab (ZLAB) is Hiding in Plain Sight
Zai Lab (ZLAB) crashed to $16.30 in early 2026 due to forced institutional selling. However, sharp hedge fund RA Capital bought a 5.2% stake at the bottom, signaling a major accumulation event hidden in dark pool data.
The TYK2 Trojan Horse: Exposing the Engineered Squeeze in Alumis Inc. (ALMS)
Alumis's stock surge is a cynical liquidity event. Insiders bought low, hyped Phase 3 data, then sold shares high in a $345M offering. Despite cash, the drug faces a crowded market and massive cash burn.
The Gravity of Intuitive Machines (LUNR): A $3.6 Billion Mispricing and the Mother of All Squeezes
LUNR is a mispriced, gov-backed space infrastructure play. Its revenue is set to quintuple in 2026. High short interest and a tiny, locked-up float create a massive squeeze potential.
The $6.7 Billion Mirage: Why Centene's (CNC) Manufactured Crisis is the Ultimate Bear Trap
Centene's $6.7B non-cash impairment triggered a sell-off, but the firm has $17B cash. Sophisticated funds are buying as insiders align for a major stock price recovery.
The Great Robinhood Heist: Buy the Dip Insiders Created
Robinhood stock crashed 55% despite strong fundamentals, as insiders sold millions of shares at peak prices. Now, extreme off-exchange trading signals suggest major institutional accumulation at the $68 level.